Dynamics of profibrogenic factors in patients with chronic pancreatitis following therapy with allogenic multipotent mesenchymal stromal cells

Cell therapy of chronic pancreatitis complications is a relevant strategy in regenerative medicine. However, the lack of research on the antifibrogenic effects of multipotent mesenchymal stromal cells (MMSCs) and the limited number of clinical trials leave many open questions regarding the mechanisms by which they regulate fibrogenesis. This article analyzes the dynamics of synthesis of extracellular matrix components (α smooth muscle actin and fibronectin) and of the principal activator of pancreatic stellate cells (transforming growth factor β) in the serum of patients with chronic pancreatitis after cell therapy based on biomedical cell product of allogeneic MMSCs administration. It has been shown that MMSCs were capable of suppressing the profibrogenic components production for 1 year in patients with chronic pancreatitis, both after intraoperative parapancreatic and after intravenous administration of biomedical cell product.

1. Chang M., Chen W., Xia R., Peng Y., Niu P., Fan H. Pancreatic stellate cells and the targeted therapeutic strategies in chronic pancreatitis. Molecules, 2023, vol. 28, no. 14, art. 5586. https://doi.org/10.3390/molecules28145586

2. Taha H. S., Moustafa E. M., Moawed F. S. M., Hegazy M. G. A. Curative role of mesenchymal stromal cells in chronic pancreatitis: Modulation of MAPK and TGF-β1/SMAD factors. International Journal of Immunopathology and Pharmacology, 2021, vol. 35. https://doi.org/10.1177/20587384211054036

3. Peng L., Hu Y., Zhang X., Tan C., Yang C., Liu T., Ferdek P. E., Yin S., Wang L., Huang W., Zhang Y. TGF-β1/SMAD3-mediated non-canonical hedgehog signaling promotes pancreatic stellate cell activation and fibrosis in chronic pancreatitis. International Journal of Biological Sciences, 2025, vol. 21, no. 15, pp. 6978–6996. https://doi.org/10.7150/ijbs.108149

4. Shuleiko A. Ch. Selection of pathogenetically justified surgical treatment for chronic pancreatitis: PhD thesis. Minsk, 2022. 47 p. (in Russian).

5. Qin L., Liu N., Bao C., Yang D., Ma G., Yi W., Xiao G., Cao H. Mesenchymal stem cells in fibrotic diseases – the two sides of the same coin. Acta Pharmacologica Sinica, 2023, vol. 44, pp. 268–287. https://doi.org/10.1038/s41401-022-00952-0

6. Nizheharodava D. B., Kandratovich T. V., Halabarodzka M. V., Mahmudov A. M., Savitskaya T. V., Vladimirskaya T. E., Strinovich A. L., Zafranskaya M. M. The effect of mesenchymal stem cells based cell therapy on morphofunctional and molecular-biological parameters of fibrogenesis in experimental modeling. Vestnik Fonda fundamental’nykh issledovanii = Vestnik of the Foundation for Fundamental Research, 2017, no. 2/80, pp. 90–105 (in Russian).

7. Zafranskaya M. M., Fedulov A. S., Demidchik Yu. E. The Effect of Mesenchymal Stem Cells in Cell Therapy of Multiple Sclerosis. Minsk, 2016. 213 p. (in Russian).

8. Varabei A. V., Dybau A. G., Zafranskaya M. M., Shuleiko A. Ch., Adamovich H. Yu., Starastsin A. M., Nizheharodava D. B., But-Husaim H. V., Hryko S. M., Bachko U. N., Kazlouski A. A. Selective infusion into the mesenteric arteries of autologous multipotent mesenchymal stromal cells in the treatment of ulcerative colitis. Khirurgiya. Vostochnaya Evropa = Surgery. Eastern Europe, 2024, vol. 13, no. 3, pp. 319–327 (in Russian). https://doi.org/10.34883/PI.2024.13.3.016

9. Jin T., Cheng H., Li M., Wei X., Wang X., Li X., Sun G., Zhang D., Hao J., Liu X. Bone marrow mesenchymal stem cells can prevent pancreatic fibrosis in mice with chronic pancreatitis by inhibiting the activation of pancreatic stellate cells. Journal of Inflammation Research, 2025, vol. 2025, no. 18, pp. 11041–11053. https://doi.org/10.2147/JIR.S534110

10. Sun Z., Gou W., Kim D., Dong X., Strange C., Tan Y.,Adams D. B., Wang H.Adipose stem cell therapy mitigates chronic pancreatitis via differentiation into acinar-like cells in mice. Molecular Therapy, 2017, vol. 25, no. 11, pp. 2490–2501. https://doi.org/10.1016/j.ymthe.2017.06.016

11. Ma Z., Zhou J., Yang T., Xie W., Song G., Song Z., Chen J. Mesenchymal stromal cell therapy for pancreatitis: Progress and challenges. Medicinal Research Reviews, 2021, vol. 41, no. 4, pp. 2474–2488. https://doi.org/10.1002/med.21801

12. Xu X., Yu H., Sun L., Zheng C., Shan Y., Zhou Z., Wang C., Chen B.Adipose‑derived mesenchymalstem cells ameliorate dibutyltin dichloride‑induced chronic pancreatitis by inhibiting the PI3K/AKT/mTOR signaling pathway. Molecular Medicine Reports, 2020, vol. 21, no. 4, pp. 1833–1840. https://doi.org/10.3892/mmr.2020.10995

13. Vinokurova L. V., Lesko K. A., Bordin D. S., Dubtsova E. A., Tyulyaeva E. Yu., Varvanina G. G. Research of new approaches of differential diagnosis of pancreatic lesions. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology, 2019, no. 3, pp. 24–30 (in Russian). https://doi.org/10.31146/1682-8658-ecg-163-3-24-3